Attention ESSA Pharma Investors: Important Information Regarding Securities Purchased During the Class Period
New York, NY – Feb. 11, 2025 – Rosen Law Firm, a global investor rights law firm, alerts investors of ESSA Pharma Inc. (NASDAQ: EPIX) regarding a potential securities class action lawsuit. If you purchased ESSA Pharma securities between December 12, 2023 and October 31, 2024, inclusive (the “Class Period”), you may be entitled to compensation. The lead plaintiff deadline is fast approaching, and investors are encouraged to contact the firm before March 25, 2025.
Background on ESSA Pharma
ESSA Pharma is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of rare and debilitating diseases. The company’s lead product candidate, Plenadotus B, is a first-in-class, oral, and selective androgen receptor antagonist (SARA) for the treatment of prostate cancer.
The Allegations
The investigation concerns potential misrepresentations and/or omissions by ESSA Pharma’s management regarding the development and commercial prospects of Plenadotus B. Specifically, the lawsuit alleges that the Company made false and/or misleading statements and/or failed to disclose: (1) that the data from ESSA Pharma’s Phase 2 clinical trial for Plenadotus B did not meet its primary endpoint, (2) that the Company was experiencing difficulties in designing a successful Phase 3 clinical trial, and (3) that, as a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
What This Means for Investors
If you purchased ESSA Pharma securities during the Class Period, you may be able to recover your losses as a member of the proposed class. The lead plaintiff deadline is March 25, 2025. To be eligible for compensation, you do not need to serve as a lead plaintiff. You may, however, be able to serve as a lead plaintiff, which would allow you to direct the litigation and receive certain other benefits.
How This Affects the World
The implications of this potential securities class action lawsuit go beyond just ESSA Pharma investors. This lawsuit could potentially have far-reaching effects on the biotech industry as a whole. If the allegations are proven true, it could lead to increased scrutiny of other biotech companies and their clinical trial data. This, in turn, could lead to a decrease in investor confidence in the biotech sector and potentially impact the valuations of other companies in the industry.
Conclusion
If you purchased ESSA Pharma securities during the Class Period and believe that you may be entitled to compensation, please contact Rosen Law Firm before March 25, 2025. Our firm has significant experience in securities class action litigation and is prepared to help you recover your losses. Together, we can hold those responsible for any misrepresentations or omissions accountable and seek justice for all affected investors.
- Rosen Law Firm reminds ESSA Pharma investors of a potential securities class action lawsuit.
- The Class Period is from December 12, 2023 to October 31, 2024.
- The lead plaintiff deadline is March 25, 2025.
- Allegations include potential misrepresentations and/or omissions regarding Plenadotus B’s development and commercial prospects.
- Investors may be able to recover their losses as a member of the proposed class.
- The lawsuit could have far-reaching effects on the biotech industry.
- Contact Rosen Law Firm before March 25, 2025, for assistance.
